March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Soluble IL-6R and Neuroprotection of Retinal Ganglion Cells in Glaucoma
Author Affiliations & Notes
  • Heather M. Cathcart
    Vanderbilt Eye Institute, Vanderbilt Univ Medical Center, Nashville, Tennessee
  • Rebecca M. Sappington
    Vanderbilt Eye Institute, Vanderbilt Univ Medical Center, Nashville, Tennessee
  • Footnotes
    Commercial Relationships  Heather M. Cathcart, None; Rebecca M. Sappington, None
  • Footnotes
    Support  NIH Grant EY020496 (RMS); NIH Core Grant EY08126 (VVRC); Career Development Award, Research to Prevent Blindness, Inc. (RMS); and Unrestricted funds from Research to Prevent Blindness, Inc. (VEI)
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 6585. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Heather M. Cathcart, Rebecca M. Sappington; Soluble IL-6R and Neuroprotection of Retinal Ganglion Cells in Glaucoma. Invest. Ophthalmol. Vis. Sci. 2012;53(14):6585.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Interleukin-6 (IL-6) trans-signaling mediated through soluble IL-6 receptor (sIL-6R) plays a critical role in the pathology of numerous chronic inflammatory diseases. The objective of this study was to examine the neurobiological relevance of IL-6 trans-signaling in the onset and progression of retinal ganglion cell (RGC) pathology in a chronic murine model of glaucoma.

Methods: : Using a co-immunolabeling assay, the presence of sIL-6R and transmembrane IL-6R alpha (IL-6R alpha) were assessed simultaneously in whole mount retinas. For this assay, two antibodies against IL-6R were used; the first is specific to the cytoplasmic peptide sequence, while the second is specific to the extracellular sequence. IL-6R alpha was identified by co-localization of both antibodies whereas sIL-6R was revealed by the presence of only the extracellular antibody. Furthermore, IL-6R alpha, sIL-6R, gp130 and soluble gp130 (sgp130) were quantified from whole retina fractions of soluble and trans-membrane protein and both fractions were analyzed using the Milliplex Map mouse soluble cytokine receptor immunoassay.

Results: : In retina whole mounts from 4 and 7 month old DBA/2 and C57BL/6 mice, we found that both forms of IL-6R were associated with SMI-31 in RGCs. However, localization of IL-6R alpha was primarily associated with RGC somas in C57BL/6 mice, while strong sIL-6R labeling was associated with RGC axons in DBA/2 mice. The cytokine receptor immunoassay confirmed that membrane bound IL-6R alpha concentration increased in DBA/2 (19.48 pg/ml) retinas when compared to retinas from C57BL/6 (14.74 pg/ml) mice. The immunoassay also revealed that sIL-6R was slightly decreased in DBA/2 (5.08 pg/ml) retinas when compared with concentrations from retinas of C57BL/6 (7.14 pg/ml) mice. Concentrations of the common signal transduction protein, gp130, was also decreased in DBA/2 retinas (137.36 pg/ml; C57BL/6 224.17 pg/ml), while sgp130 concentrations were similar (DBA/2 7.70 pg/ml; C57BL/6 8.61 pg/ml).

Conclusions: : These data indicate that sIL-6R is associated with RGC axons and somas and that soluble and transmembrane IL-6R and gp130 expression varies with increased intraocular pressure, implicating IL-6 trans-signaling in RGC pathology in chronic glaucoma.

Keywords: receptors • ganglion cells • neuroprotection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×